92 related articles for article (PubMed ID: 21204722)
1. Targetable molecular pathways in classical Hodgkin's lymphoma.
Adams H; Obermann EC; Dirnhofer S; Tzankov A
Expert Opin Investig Drugs; 2011 Feb; 20(2):141-51. PubMed ID: 21204722
[TBL] [Abstract][Full Text] [Related]
2. Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.
Carbone A; Gloghini A; Castagna L; Santoro A; Carlo-Stella C
J Pathol; 2015 Sep; 237(1):4-13. PubMed ID: 25953622
[TBL] [Abstract][Full Text] [Related]
3. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
4. Novel therapy for Hodgkin lymphoma.
Batlevi CL; Younes A
Hematology Am Soc Hematol Educ Program; 2013; 2013():394-9. PubMed ID: 24319210
[TBL] [Abstract][Full Text] [Related]
5. Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.
Carlo-Stella C; Santoro A
Biomark Med; 2015; 9(8):807-17. PubMed ID: 26223461
[TBL] [Abstract][Full Text] [Related]
6. PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher.
Allen PB; Gordon LI
Expert Rev Hematol; 2016 Oct; 9(10):939-49. PubMed ID: 27622603
[TBL] [Abstract][Full Text] [Related]
7. TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells.
Guo F; Sun A; Wang W; He J; Hou J; Zhou P; Chen Z
Mol Immunol; 2009 Aug; 46(13):2441-8. PubMed ID: 19540595
[TBL] [Abstract][Full Text] [Related]
8. Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy.
Montanari F; Diefenbach CS
Clin Adv Hematol Oncol; 2015 Aug; 13(8):518-24. PubMed ID: 26351815
[TBL] [Abstract][Full Text] [Related]
9. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
Jazirehi AR; Huerta-Yepez S; Cheng G; Bonavida B
Cancer Res; 2005 Jan; 65(1):264-76. PubMed ID: 15665303
[TBL] [Abstract][Full Text] [Related]
10. Dimeric procyanidin B2 inhibits constitutively active NF-kappaB in Hodgkin's lymphoma cells independently of the presence of IkappaB mutations.
Mackenzie GG; Adamo AM; Decker NP; Oteiza PI
Biochem Pharmacol; 2008 Apr; 75(7):1461-71. PubMed ID: 18275936
[TBL] [Abstract][Full Text] [Related]
11. Hodgkin's lymphoma: current treatment strategies and novel approaches.
Eichenauer DA; Fuchs M; Borchmann P; Engert A;
Expert Rev Hematol; 2008 Oct; 1(1):63-73. PubMed ID: 21083007
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.
Böll B; Eltaib F; Reiners KS; von Tresckow B; Tawadros S; Simhadri VR; Burrows FJ; Lundgren K; Hansen HP; Engert A; von Strandmann EP
Clin Cancer Res; 2009 Aug; 15(16):5108-16. PubMed ID: 19671844
[TBL] [Abstract][Full Text] [Related]
13. Composite marginal zone B-cell lymphoma and classical Hodgkin's lymphoma: a clinicopathological study of 12 cases.
Zettl A; Rüdiger T; Marx A; Müller-Hermelink HK; Ott G
Histopathology; 2005 Feb; 46(2):217-28. PubMed ID: 15693895
[TBL] [Abstract][Full Text] [Related]
14. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells.
Hirsch B; Hummel M; Bentink S; Fouladi F; Spang R; Zollinger R; Stein H; Dürkop H
Am J Pathol; 2008 Feb; 172(2):510-20. PubMed ID: 18187570
[TBL] [Abstract][Full Text] [Related]
15. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Geyer HL; Mesa RA
Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
[TBL] [Abstract][Full Text] [Related]
16. [The action mechanisms of unclassical NF-kappaB activity and TRAF3 expression in Hodgkin's lymphoma cells].
Guo F; Wang WJ; Sun AN; Zhou P; Chen ZX
Zhonghua Xue Ye Xue Za Zhi; 2009 Oct; 30(10):678-82. PubMed ID: 19954665
[TBL] [Abstract][Full Text] [Related]
17. The kinase NIK as a therapeutic target in multiple myeloma.
Gardam S; Beyaert R
Expert Opin Ther Targets; 2011 Feb; 15(2):207-18. PubMed ID: 21204728
[TBL] [Abstract][Full Text] [Related]
18. Salvage therapy in Hodgkin's lymphoma.
Mendler JH; Friedberg JW
Oncologist; 2009 Apr; 14(4):425-32. PubMed ID: 19342476
[TBL] [Abstract][Full Text] [Related]
19. STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line.
Baus D; Nonnenmacher F; Jankowski S; Döring C; Bräutigam C; Frank M; Hansmann ML; Pfitzner E
Leukemia; 2009 Oct; 23(10):1885-93. PubMed ID: 19440213
[TBL] [Abstract][Full Text] [Related]
20. Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed-Sternberg cells.
Schwarzer R; Dörken B; Jundt F
Leukemia; 2012 Apr; 26(4):806-13. PubMed ID: 21946908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
